|
As reported by the field clinical specialist, both femoral accesses was calcified and there were bilateral iliac stents.However, alternative access wasn't feasible.The valve stuck in the right iliac stent near iliac bifurcation after it had exited the esheath.The implanter tried to navigate through it.Later, looking at the aortic and iliac bleeding, implanter deployed the valve in the abdominal aorta and balloon tamponade was performed to stop bleeding.Vascular surgery team took over.Later, patient passed away due to excessive bleeding.The root cause of the aortic and iliac bleeding was related to the pushing the valve through the stent.The valve was successfully implanted.There was no central leak.There was no use error that led to any negative outcomes or patient injury.There was no device malfunction/difficulty using the device during the case.
|
|
Update to b4, g3, g6 and h2.Corrected h6 type of investigation, investigation findings, and investigation conclusions.The device was not returned for evaluation.The investigation was conducted, using engineering technical summary written by edwards lifesciences.This issue is not related to a manufacturing deficiency, design, reliability, use error, labeling, or device related infection and therefore dhr review and manufacturing mitigations review are not required for these complaint events.A review of edwards lifesciences risk management documentation was performed for this case.The reported event is an anticipated risk of the transcatheter heart valve procedure, additional assessment of the failure mode is not required at this time.Through extensive complaint investigations, difficulty or inability in tracking the delivery system to the landing zone, including traversing the aortic arch and crossing the native annulus/bioprosthesis has not been associated with device malfunctions or manufacturing nonconformances.Rather, the root cause for these events have historically been due to patient factors, poor guidewire management, damaged guidewire, and/or excessive manipulation of the flex wheel.The complaint for insertion difficulty has been confirmed based on the information available to date.Any updates or additional findings will be submitted in accordance with fda reporting requirements.Available information suggests patient factors likely contributed to the event as the customer reported "both femoral accesses was calcified and there were bilateral iliac stents" and that "valve stuck in the right iliac stent".Patient factors (i.E.Calcification, tortuosity, small vessel size, pre-existing vascular stent) may cause constrained sections of the anatomy that interferes with passage of the delivery system and causes difficulty during tracking.A product risk assessment (pra) is not required because there are no confirmed product or labeling/ifu/training material non-conformances affecting distributed product and no other triggers have been met.A capa/scar is not required because an edwards/supplier defect which could have resulted in the complaint was not confirmed.The ifu and training manuals have been reviewed and no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.
|